HCV RNA quantification with different assays: Implications for protease-inhibitor-based response-guided therapy

Antiviral Therapy

Volumn 19, Issue 6, 2014, Pages 559-567

  Fevery, Bart ^a   Susser, Simone ^b   Lenz, Oliver ^a   Cloherty, Gavin ^c   Perner, Dany ^b   Picchio, Gaston ^d   Sarrazin, Christoph ^b  

^a Janssen Infectious Diseases BVBA   (Belgium)

^b GOETHE UNIVERSITY   (Germany)

^c Abbott Molecular Inc   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; SIMEPREVIR; VIRUS RNA; ANTIVIRUS AGENT; DIAGNOSTIC KIT; PROTEINASE INHIBITOR;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE GUIDED THERAPY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIROTHERAPY; VIRUS LOAD; DIAGNOSTIC KIT; GENETICS; HEPACIVIRUS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TIME; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84898802152     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2760     Document Type: Article

References (24)

1. Al Olaby RR, Azzazy HM. Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. Expert Rev Mol Diagn 2011; 11:53-64.
2. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011; 17:116-121.
3. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol 2005; 43:425-433.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36:S65-S73.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
7. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
8. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
9. Craxi A, Koutsounas S, Ogurtsov P, et al. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. J Viral Hepat 2012; 19:e120-e125.
10. Victrelis® (boceprevir) capsules for oral use. Highlights of prescribing information 2013. Merck & Co., Inc. Whitehouse Station, NJ, USA. (Updated 2013. Accessed 11 July 2013.) Available from http://www.merck.com/product/ usa/pi-circulars/v/victrelis/victrelis-pi.pdf.
11. Incivek™ (telaprevir) film coated tablets, for oral use. Highlights of prescribing information 2013. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA. (Updated April 2013. Accessed 11 July 2013.) Available from http://pi.vrtx.com/files/uspi-telaprevir.pdf
12. Kwo PY. Response-guided therapy for HCV. Gastroenterol Hepatol (NY) 2011; 7:43-45.
13. Reddy KR, Lin F, Zoulim F. Response-guided and -unguided treatment of chronic hepatitis C. Liver Int 2012; 32 Suppl 1:64-73.
14. Le Guillou-Guillemette H, Lunel-Fabiani F. Detection and quantification of serum or plasma HCV RNA: mini review of commercially available assays. Methods Mol Biol 2009; 510:3-14.
15. Abbott RealTime HCV. Package insert 2011. Abbott Molecular, Inc., Des Plaines, IL, USA. (Updated 1 May 2011. Accessed 11 April 2013.) Available from http://www.abbottmolecular.com/ static/cms-workspace/pdfs/US/Abbott-RealTime-HCV-PI.pdf
16. COBAS® TaqMan® HCV Test, v2.0. Product information 2013. Roche Molecular Systems, Pleasanton, CA, USA. (Updated 2013. Accessed 11 April 2013.) Available from http://molecular.roche.com/ASSAYS/Pages/ COBASTaqManHCVTestv20HPS.aspx
17. Fried MW, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR Phase IIb study. Hepatology 2011; 54:1429A.
18. Vermehren J, Yu ML, Monto A, et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011; 52:133-137.
19. Colucci G, Ferguson J, Harkleroad C, et al. Improved COBAS TaqMan hepatitis C virus test (version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007; 45:3595-3600.
20. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
21. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
22. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55:1048-1057.
23. Ikezaki H, Furusyo N, Ihara T, et al. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. J Infect Chemother 2011; 17:737-743.
24. Ogawa E, Furusyo N, Murata M, et al. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevirbased triple therapy: a comparison of two real-time PCR assays. Antiviral Res 2013; 99:119-124